Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.
Gallagher EJ, Moore H, Lacouture ME, Dent SF, Farooki A, Goncalves MD, Isaacs C, Johnston A, Juric D, Quandt Z, Spring L, Berman B, Decker M, Hortobagyi GN, Kaffenberger BH, Kwong BY, Pluard T, Rao R, Schwartzberg L, Broder MS. Gallagher EJ, et al. Among authors: hortobagyi gn. NPJ Breast Cancer. 2024 Jan 31;10(1):12. doi: 10.1038/s41523-024-00613-x. NPJ Breast Cancer. 2024. PMID: 38297009 Free PMC article.
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
Yardley DA, Hart L, Favret A, Blau S, Diab S, Richards D, Sparano J, Beck JT, Richards P, Ward P, Ramaswamy B, Tsai M, Blackwell K, Pluard T, Tolaney SM, Esteva FJ, Truica CI, Alemany C, Volas-Redd G, Shtivelband M, Purkayastha D, Dalal AA, Miller M, Hortobagyi GN. Yardley DA, et al. Among authors: hortobagyi gn. Clin Breast Cancer. 2019 Aug;19(4):268-277.e1. doi: 10.1016/j.clbc.2019.02.007. Epub 2019 Feb 28. Clin Breast Cancer. 2019. PMID: 31160171 Clinical Trial.
Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221).
Mongiovi JM, Zirpoli GR, Cannioto R, Sucheston-Campbell LE, Hershman DL, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Thomas Budd G, Albain KS, Ambrosone CB, McCann SE. Mongiovi JM, et al. Among authors: hortobagyi gn. Breast Cancer Res. 2018 Nov 28;20(1):146. doi: 10.1186/s13058-018-1077-9. Breast Cancer Res. 2018. PMID: 30486865 Free PMC article.
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer.
Yao S, Sucheston LE, Zhao H, Barlow WE, Zirpoli G, Liu S, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB. Yao S, et al. Among authors: hortobagyi gn. Pharmacogenomics J. 2014 Jun;14(3):241-7. doi: 10.1038/tpj.2013.32. Epub 2013 Sep 3. Pharmacogenomics J. 2014. PMID: 23999597 Free PMC article. Clinical Trial.
Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study.
Zirpoli GR, McCann SE, Sucheston-Campbell LE, Hershman DL, Ciupak G, Davis W, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Budd GT, Albain KS, Ambrosone CB. Zirpoli GR, et al. Among authors: hortobagyi gn. J Natl Cancer Inst. 2017 Dec 1;109(12):djx098. doi: 10.1093/jnci/djx098. J Natl Cancer Inst. 2017. PMID: 29546345 Free PMC article.
Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer.
Cannioto RA, Attwood KM, Davis EW, Mendicino LA, Hutson A, Zirpoli GR, Tang L, Nair NM, Barlow W, Hershman DL, Unger JM, Moore HCF, Isaacs C, Hobday TJ, Hortobagyi GN, Gralow JR, Albain KS, Budd GT, Ambrosone CB. Cannioto RA, et al. Among authors: hortobagyi gn. JAMA Netw Open. 2023 May 1;6(5):e2311673. doi: 10.1001/jamanetworkopen.2023.11673. JAMA Netw Open. 2023. PMID: 37140922 Free PMC article.
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, Hortobagyi GN, Yee D, Smith IE, Chavez-MacGregor M, Nanda R, McArthur HL, Spring L, Reeder-Hayes KE, Ruddy KJ, Unger PS, Vinayak S, Irvin WJ Jr, Armaghani A, Danso MA, Dickson N, Turner SS, Perkins CL, Carey LA. Moy B, et al. Among authors: hortobagyi gn. J Clin Oncol. 2021 Dec 10;39(35):3938-3958. doi: 10.1200/JCO.21.01374. Epub 2021 Jul 29. J Clin Oncol. 2021. PMID: 34324366
Supplement use during an intergroup clinical trial for breast cancer (S0221).
Zirpoli GR, Brennan PM, Hong CC, McCann SE, Ciupak G, Davis W, Unger JM, Budd GT, Hershman DL, Moore HC, Stewart J, Isaacs C, Hobday T, Salim M, Hortobagyi GN, Gralow JR, Albain KS, Ambrosone CB. Zirpoli GR, et al. Among authors: hortobagyi gn. Breast Cancer Res Treat. 2013 Feb;137(3):903-13. doi: 10.1007/s10549-012-2400-2. Epub 2013 Jan 10. Breast Cancer Res Treat. 2013. PMID: 23306462 Free PMC article.
1,102 results